Vinyltrimethoxysilane

1.13 @25 °C

Specific Density: 0.94 (water = 1)

123 °C @760 [mm Hg]

123°C at 1013 hPa (converted to 101.3 kPa) (760 mm Hg)

FCS -> FDA Cumulative Estimated Daily Intake (CEDI)

FCS -> FDA Inventory of Effective Food Contact Substance (FCS) Notifications

Light yellow liquid; [Aldrich MSDS] Colorless liquid with a fruity odor; [Alfa Aesar MSDS]

Liquid (at standard temperature and pressure)

Warning

H317: May cause an allergic skin reaction [Warning Sensitization, Skin]

P261, P272, P280, P302+P352, P321, P333+P317, P362+P364, and P501 (click each P-code to see the statement)

This chemical does not meet GHS hazard criteria for 7.7% (104 of 1358) of reports.

Danger

H226 (55%): Flammable liquid and vapor [Warning Flammable liquids]

Chemical: Silane, ethenyltrimethoxy-

Status: Active Update: 05-04-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/14728

Trimethoxyvinylsilane: Does not have an individual approval but may be used under an appropriate group standard

Dermal LD50 (rabbit) = 3.36 mL/kg; Oral LD50 (rat) = 7.34 mL/kg; [ChemIDplus] A mild skin and eye irritant; Causes somnolence, ataxia, and dermatitis in dermal lethal-dose studies of rabbits; Causes changes in fluid intake, hematuria, and weight loss in 9-day intermittent inhalation study of rats (750 ppm/6hr/day); [RTECS] Sensitive to moisture; A skin irritant; May cause serious eye injury; Harmful by inhalation; [Alfa Aesar MSDS]

Flam. Liq. 3 (55%)

Not Classified

Skin sensitisation - category 1B

Flammable liquids - Category 2

Skin sensitization - Category 1B

Skin Sens. 1B

10 [ppm]

20 [ppm]

120 [ppm]

The subchronic (14-week), whole-body inhalation study (6 h/day, 5 days/week) in F344 rats was used as the critical study for the derivation of the Workplace Environmental Exposure Level (WEEL). The No-Observed-Adverse-Effect Concentration (NOAEC) of 100 ppm (605 mg/m3) was used as the point of departure (PoD). Adjustment factors for subchronic to chronic extrapolation and intra-individual variability were applied to the NOAEC to develop the health-based WEEL value of 10 ppm as the 8-hour time-weighted average (TWA).

Experimental animal studies have shown that VTMS exhibits low acute toxicity when exposed via oral, dermal, and inhalation routes. It is not a dermal or eye irritant. A weight of evidence assessment of four dermal sensitization studies in guinea pigs indicates that VTMS is not a dermal sensitizer. However, one additional study yielded positive results, leading ECHA to classify VTMS as Category 1B, indicating it may cause an allergic skin reaction. VTMS is not considered genotoxic based on in vitro and in vivo studies. Various experimental animal studies have demonstrated that VTMS does not have reproductive or developmental effects. Short-term oral administration of VTMS for 28 days in rats resulted in treatment-related effects in the urinary bladder and kidney. In a 14-week inhalation study in rats, VTMS exposure was linked to histopathological changes in the kidney and urinary bladder. However, an expert panel review concluded that these observations were adaptive responses to physical or chemical irritant(s) in the urine. The NOAEC of 100 ppm (605 mg/m³) from the 14-week inhalation study was used as the point of departure for deriving the health-based WEEL.

The typical concentration of VTMS in industrial products is from 1 to 2%. VTMS undergoes reactions, resulting in minimal or no residual chemical in the final products. It serves as a coupling agent for plastics and wire and cable pipes, acts as a moisture scavenger in sealants, and functions as a co-monomer in latex dispersions to enhance adhesion on inorganic surfaces. VTMS is managed within closed systems (hard piped) in manufacturing environments, and it is not used in consumer products.